The director of the National Institutes of Health and his principal deputy are touting their success at ‘curing’ the agency of its self-inflicted DEI disability. 

Milestone Pharmaceuticals will be selling etripamil under the brand name Cardamyst. It is expected to hit the U.S. market in early 2026.

Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances.

Published Friday in JAMA, scientists recently explored a risk-based mammography tactic that tailors regular imaging regimens to each individual’s danger of developing the disease. 

Alleged transgressions took place between February and August, including the FDA rejecting Telix’s application for a new brain cancer imaging agent. 

DECT systems allow for a contrast dose reduction of up to 25% during computed tomography pulmonary angiography exams.

The list, which was updated during the first week of December, now contains over 1,300 artificial intelligence-enabled medical devices.  

Yale New Haven failed to notify parents about the use of the cow-based formula, which they expressly asked staff not to use. A judge found that the hospital failed to stock a human alternative, known to be safer for premature newborns.